$26.22 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to post sales of $26.22 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $21.15 million and the highest is $39.80 million. Nektar Therapeutics reported sales of $95.47 million during the same quarter last year, which would suggest a negative year over year growth rate of 72.5%. The business is scheduled to issue its next earnings report on Thursday, March 7th.

According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $1.18 billion for the current year, with estimates ranging from $1.17 billion to $1.20 billion. For the next year, analysts anticipate that the business will report sales of $457.12 million, with estimates ranging from $135.00 million to $1.18 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.07. The company had revenue of $27.80 million for the quarter, compared to analyst estimates of $26.08 million. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. Nektar Therapeutics’s revenue for the quarter was down 81.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.37 EPS.

NKTR has been the topic of several recent analyst reports. BidaskClub lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 18th. HC Wainwright set a $54.00 target price on shares of Nektar Therapeutics and gave the stock a “hold” rating in a report on Monday, October 22nd. Mizuho reaffirmed a “buy” rating and set a $103.00 target price on shares of Nektar Therapeutics in a report on Thursday, August 9th. Piper Jaffray Companies set a $125.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 25th. Finally, Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. Nektar Therapeutics presently has an average rating of “Buy” and an average price target of $79.55.

Shares of Nektar Therapeutics stock traded down $2.64 during trading on Friday, hitting $35.31. 4,322,822 shares of the stock were exchanged, compared to its average volume of 3,121,603. The firm has a market capitalization of $6.22 billion, a PE ratio of -64.20 and a beta of 2.91. Nektar Therapeutics has a 1-year low of $30.30 and a 1-year high of $111.36. The company has a debt-to-equity ratio of 0.13, a current ratio of 19.67 and a quick ratio of 19.55.

In other Nektar Therapeutics news, Director Dennis L. Winger sold 34,250 shares of the business’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now owns 59,875 shares of the company’s stock, valued at approximately $3,628,425. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dennis L. Winger sold 30,000 shares of the business’s stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $59.96, for a total transaction of $1,798,800.00. Following the completion of the sale, the director now directly owns 57,750 shares of the company’s stock, valued at approximately $3,462,690. The disclosure for this sale can be found here. Insiders have sold a total of 96,000 shares of company stock valued at $5,825,680 in the last ninety days. 4.31% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of NKTR. FMR LLC boosted its holdings in Nektar Therapeutics by 6.7% in the 2nd quarter. FMR LLC now owns 25,705,902 shares of the biopharmaceutical company’s stock valued at $1,255,220,000 after purchasing an additional 1,608,834 shares during the period. First Trust Advisors LP boosted its holdings in Nektar Therapeutics by 176.2% in the 3rd quarter. First Trust Advisors LP now owns 2,068,900 shares of the biopharmaceutical company’s stock valued at $126,120,000 after purchasing an additional 1,319,776 shares during the period. OppenheimerFunds Inc. boosted its holdings in Nektar Therapeutics by 7.9% in the 2nd quarter. OppenheimerFunds Inc. now owns 11,560,779 shares of the biopharmaceutical company’s stock valued at $564,512,000 after purchasing an additional 845,257 shares during the period. Advisors Asset Management Inc. bought a new stake in Nektar Therapeutics in the 2nd quarter valued at about $373,000. Finally, BB Biotech AG bought a new stake in Nektar Therapeutics in the 2nd quarter valued at about $25,636,000. 92.72% of the stock is owned by hedge funds and other institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Read More: Balance Sheet

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply